Background: This article provides an overview of direct-to-consumer (DTC) genomic services that are currently available in Greece and the legal framework within which they operate. Methods: Here, we describe the landscape of the DTC genomic testing companies and laboratories by conducting a systematic Ιnternet search for relevant websites. We examine the existing legal framework regarding genetic testing in Greece by a review of present regulation. Although Greece does not have explicit legal provisions for DTC genomics, several other laws, including soft law mechanisms, create the broader legal framework within which DTC genomic services may exist. Results/Conclusions: While the current legal framework creates a flexible environment that is conducive to DTC genomic operations, it is also ambiguous about the legality of some specific services. Given the growing DTC activity in Greece, we argue that it is important to both enforce compliance with existing law and clarify legal ambiguities that may risk limiting the power of legal protections that ought to be afforded to consumers.

1.
Ministry of Health National Organization of Health Providers. http://www.eopyy.gov.gr/MedSupplier.
2.
Hellenic Association of Medical Geneticists. Unofficial registry of the Association. http://www.sige.gr/index.php/en/genetics/links/60-labslinks.
3.
Patrinos GP, Baker DJ, Al-Mulla F, Vasiliou V, Cooper DN: Genetic tests obtainable through pharmacies: the good, the bad, and the ugly. Hum Genomics 2013;7:17.
4.
Hellenic Association of Medical Geneticists: Announcement on genome diagnostics. http://www.sige.gr/index.php/en/genetics/laws/97-geneticscomercial.
5.
Prainsack B, Vayena E: Beyond the clinic: ‘direct-to-consumer' genomic profiling services and pharmacogenomics. Pharmacogenomics 2013;14:403-412.
6.
Mai Y, Koromila T, Sagia A, Cooper DN, Vlachopoulos G, Lagoumintzis G, Kollia P, Poulas K, Stathakopoulos V, Patrinos GP: A critical view of the general public's awareness and physicians' opinion of the trends and potential pitfalls of genetic testing in Greece. Pers Med 2011;8:551-561.
7.
Sagia A, Cooper DN, Poulas K, Stathakopoulos V, Patrinos GP: Critical appraisal of the private genetic and pharmacogenomic testing environment in Greece. Pers Med 2011;8:413-420.
8.
Hellenic National Bioethics Commission (HNBC): Report on Direct-to-Consumer Genetic Testing. http://www.bioethics.gr/images/pdf/ENGLISH/OPINIONS_REPORTS/REPORT_DTC_genetic_tests-Final-EN.pdf.
9.
Supreme Court (Arios Pagos). Decision 908/2011. http://www.dsanet.gr/Epikairothta/Nomologia/ap908_2011.htm.
10.
Federation of European Academies of Medicine and European Academies Science Advisory Council: Direct-to-Consumer Genetic Testing for Health-Related Purposes in the European Union. EASAC policy report 18. July 2012.
11.
Borry P, van Hellemondt RE, Sprumont D, Jales CF, Rial-Sebbag E, Spranger TM, Curren L, Kaye J, Nys H, Howard H: Legislation on direct-to-consumer genetic testing in seven European countries. Eur J Hum Genet 2012;20:715-721.
12.
Wright CF, Hall A, Zimmern RL: Regulating direct-to-consumer genetic tests: what is all the fuss about? Genet Med 2011;13:295-300.
13.
Soini S: Genetic testing legislation in Western Europe - a fluctuating regulatory target. J Community Genet 2012;3:143-153.
14.
Grimaldi KA, Look MP, Scioli GA, Clavero JC, Marinos S, Tagaris T: Personal genetics: regulatory framework in Europe from a service provider's perspective. Eur J Hum Genet 2011;19:382-388.
15.
Berwouts S, Fanning K, Morris MA, Barton DE, Dequeker E: Quality assurance practices in Europe: a survey of molecular genetic testing laboratories. Eur J Hum Genet 2012;20:1118-1126.
16.
Gollust SE, Hull SC, Wilfond BS: Limitations of direct-to-consumer advertising for clinical genetic testing. JAMA 2002;288:1762-1767.
17.
Hayden EC: Informed consent: a broken contract. Nature 2012;486:312-314.
18.
Saukko P: State of play in direct-to-consumer genetic testing for lifestyle-related diseases: market, marketing content, user experiences and regulation. Proc Nutr Soc 2013;72:53-60.
19.
Panhellenic Association of Bioscientists: Request to the Ministry of Education to ban public talks about genetic testing at schools. http://www.pev.gr/index.php/2008-12-24-17-44-01/2008-12-27-14-17-42/306-qq.
20.
Scleckser K: Physician participation in direct-to-consumer genetic testing: pragmatism or paternalism? Harv J Law Technol 2013;26:695-730.
21.
Food and Drug Administration (FDA): Letter to Pathway Genomics to hold off selling Pathway Genomics Genetic Health Report kit at Walgreens. 2010. http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/ucm211866.htm.
22.
Ministry of Health Central Council of Health Issues: Decision 2/204 about Genetics: Organization of Genetic Centers - Qualification of Geneticists, 21.9.2006.
23.
Panhellenic Association of Bioscientists: Letter to the Ministry of Health http://www.pev.gr/eggrafa/pdf/BioSc%20DEP%20for%20Genetic%20Specialties%20%202%2012%5B1%5D.pdf.
24.
Hellenic Association of Medical Geneticists: Letter to the Ministry of Health on February 9th, 2012. http://www.sige.gr/documents/nomothesia/2012-02-09-Loverdos.pdf.
25.
Vayena E, Mastroianni A, Kahn J: Caught in the web: informed consent for online health research. Sci Transl Med 2013;5:173fs176.
26.
Vayena E, Mastroianni A, Kahn J: Ethical issues in health research with novel online sources. Am J Public Health 2012;102:2225-2230.
27.
Tamir S: Direct-to-consumer genetic testing: ethical-legal perspectives and practical considerations. Med Law Rev 2010;18:213-238.
28.
Spector-Bagdady K, Pike E: Consuming Genomics: Regulating Direct-to-Consumer Genetic and Genomic Information. Nebraska Law Rev 2014;92:677-745.
29.
Vayena E: Direct-to-consumer genomics on the scales of autonomy. J Med Ethics 2014, E-pub ahead of print.
30.
Vayena E, Prainsack B: Regulating genomics: time for a broader vision. Sci Transl Med 2013;5:198ed12.
31.
Kazanis I: Reforming the Greek health system: a role for non-medical, clinical bioscientists. Health Policy 2013;109:46-51.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.